Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2015

01.03.2015

Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer

verfasst von: Desiree Jones, Fengmin Zhao, Joanna Brell, Mark A. Lewis, Charles L. Loprinzi, Matthias Weiss, Michael J. Fisch

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated how treatment-induced neuropathic symptoms are associated with patients’ quality of life (QOL) and clinician-reported difficulty in caring for patients.

Methods

Data were obtained from 3,106 outpatients with colorectal, breast, lung, or prostate cancer on numbness/tingling (N/T), neuropathic pain, and QOL. Clinicians reported the degree of difficulty in caring for patients’ physical and psychological symptoms.

Results

For all patients, moderate to severe N/T was associated with poor QOL (OR = 1.82, 95 % CI = 1.47–2.26, P < 0.001) but neuropathic pain was not (OR = 1.31, 95 % CI = 0.94–1.83, P = 0.114). Moderate to severe N/T and neuropathic pain were associated with increased care difficulty (OR = 1.49, 95 % CI = 1.27–1.74, P < 0.001 for N/T, and OR = 1.46, 95 % CI = 1.15–1.84, P = 0.002 for neuropathic pain). The association of neuropathic pain with care difficulty was most significant in patients with colorectal cancer (CRC) (OR = 2.32, 95 % CI = 1.41–3.83, P = 0.001). Baseline neuropathic pain was associated with declining QOL in CRC patients (OR = 2.08, 95 % CI = 1.21–3.58, P = 0.008).

Conclusions

Clinicians may experience increased care difficulty for patients of all cancer types with moderate to severe N/T or neuropathic pain; care difficulty due to neuropathic pain may be higher for CRC patients. Nearly half the patients of all cancer types with moderate to severe N/T may expect poor short-term QOL; CRC—but not other—patients with baseline neuropathic pain are likely to experience declining QOL.

Implications for Cancer Survivors

About half of patients with moderate to severe N/T (any cancer type) may expect poor QOL in the short term; CRC patients with baseline neuropathic pain in particular may experience declining QOL.
Literatur
2.
Zurück zum Zitat André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. doi:10.1056/NEJMoa032709.CrossRefPubMed André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. doi:10.​1056/​NEJMoa032709.CrossRefPubMed
3.
Zurück zum Zitat André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(19):3109–16. doi:10.1200/jco.2008.20.6771.CrossRef André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(19):3109–16. doi:10.​1200/​jco.​2008.​20.​6771.CrossRef
7.
Zurück zum Zitat Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438–44. doi:10.1002/cncr.27732.CrossRefPubMed Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438–44. doi:10.​1002/​cncr.​27732.CrossRefPubMed
8.
Zurück zum Zitat Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2012;20(11):2959–67. doi:10.1007/s00520-012-1428-5.CrossRef Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2012;20(11):2959–67. doi:10.​1007/​s00520-012-1428-5.CrossRef
9.
Zurück zum Zitat Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2013;21(12):3307–13. doi:10.1007/s00520-013-1905-5.CrossRef Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2013;21(12):3307–13. doi:10.​1007/​s00520-013-1905-5.CrossRef
10.
Zurück zum Zitat Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(21):2699–707. doi:10.1200/jco.2013.49.1514.CrossRef Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(21):2699–707. doi:10.​1200/​jco.​2013.​49.​1514.CrossRef
11.
Zurück zum Zitat Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171–8. doi:10.1002/cncr.27489.PubMedCentralCrossRefPubMed Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171–8. doi:10.​1002/​cncr.​27489.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(11):1472–8. doi:10.1200/jco.2010.33.0308.CrossRef Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(11):1472–8. doi:10.​1200/​jco.​2010.​33.​0308.CrossRef
13.
Zurück zum Zitat Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013. doi:10.1200/jop.2012.000863.PubMed Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013. doi:10.​1200/​jop.​2012.​000863.PubMed
14.
Zurück zum Zitat Lewis MA, Zhao F, Jones D, Loprinzi C, Brell JM, Weiss M, Fisch MJ (2014) Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal versus breast, lung or prostate cancer—results from a prospective mulitcenter study. Support Care Cancer, Under review Lewis MA, Zhao F, Jones D, Loprinzi C, Brell JM, Weiss M, Fisch MJ (2014) Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal versus breast, lung or prostate cancer—results from a prospective mulitcenter study. Support Care Cancer, Under review
15.
Zurück zum Zitat Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46.CrossRefPubMed Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46.CrossRefPubMed
16.
Zurück zum Zitat Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manag. 2005;29(3):224–37. doi:10.1016/j.jpainsymman.2004.05.008.CrossRef Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manag. 2005;29(3):224–37. doi:10.​1016/​j.​jpainsymman.​2004.​05.​008.CrossRef
17.
Zurück zum Zitat Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61(2):277–84.CrossRefPubMed Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61(2):277–84.CrossRefPubMed
18.
Zurück zum Zitat StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP. 2009. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP. 2009.
19.
Zurück zum Zitat Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJ, Mantyh P, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J (Sudbury, Mass). 2007;13(6):399–403. doi:10.1097/PPO.0b013e31815a999b.CrossRef Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJ, Mantyh P, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J (Sudbury, Mass). 2007;13(6):399–403. doi:10.​1097/​PPO.​0b013e31815a999b​.CrossRef
20.
Zurück zum Zitat Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–10.CrossRefPubMed Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–10.CrossRefPubMed
21.
Zurück zum Zitat Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA: J Am Med Assoc. 2013;309(13):1359–67. doi:10.1001/jama.2013.2813.CrossRef Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA: J Am Med Assoc. 2013;309(13):1359–67. doi:10.​1001/​jama.​2013.​2813.CrossRef
22.
Zurück zum Zitat Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutrition (Edinburgh, Scotland). 2013;32(6):888–93. doi:10.1016/j.clnu.2013.04.007.CrossRef Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutrition (Edinburgh, Scotland). 2013;32(6):888–93. doi:10.​1016/​j.​clnu.​2013.​04.​007.CrossRef
23.
Zurück zum Zitat Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/alliance). J Clin Oncol: Off J Am Soc Clin Oncol. 2013. doi:10.1200/jco.2013.52.0536. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/alliance). J Clin Oncol: Off J Am Soc Clin Oncol. 2013. doi:10.​1200/​jco.​2013.​52.​0536.
24.
Zurück zum Zitat Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Netherlands J Med. 2012;70(1):18–25. Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Netherlands J Med. 2012;70(1):18–25.
25.
Zurück zum Zitat Schroder S, Beckmann K, Franconi G, Meyer-Hamme G, Friedemann T, Greten HJ, et al. Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evidence-based Complement Alternat Med: eCAM. 2013;2013:423713. doi:10.1155/2013/423713.PubMedCentral Schroder S, Beckmann K, Franconi G, Meyer-Hamme G, Friedemann T, Greten HJ, et al. Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evidence-based Complement Alternat Med: eCAM. 2013;2013:423713. doi:10.​1155/​2013/​423713.PubMedCentral
28.
Zurück zum Zitat Postma TJ, Reijneveld JC, Heimans JJ. Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment? Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2013;24(6):1424–6. doi:10.1093/annonc/mdt173.CrossRef Postma TJ, Reijneveld JC, Heimans JJ. Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment? Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2013;24(6):1424–6. doi:10.​1093/​annonc/​mdt173.CrossRef
30.
Zurück zum Zitat Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2013. doi:10.1007/s00520-013-2075-1. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer: Off J Multinational Assoc Support Care Cancer. 2013. doi:10.​1007/​s00520-013-2075-1.
Metadaten
Titel
Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer
verfasst von
Desiree Jones
Fengmin Zhao
Joanna Brell
Mark A. Lewis
Charles L. Loprinzi
Matthias Weiss
Michael J. Fisch
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2015
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-014-0379-x

Weitere Artikel der Ausgabe 1/2015

Journal of Cancer Survivorship 1/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.